Prestige Consumer Healthcare (NYSE:PBH) Announces Earnings Results, Beats Expectations By $0.06 EPS

Prestige Consumer Healthcare (NYSE:PBH) posted its earnings results on Thursday. The company reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.06, FiscalAI reports. The business had revenue of $336.31 million during the quarter, compared to analysts’ expectations of $329.14 million. Prestige Consumer Healthcare had a return on equity of 11.28% and a net margin of 13.29%. Prestige Consumer Healthcare’s revenue for the quarter was up 22.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.07 EPS.

Here are the key takeaways from Prestige Consumer Healthcare’s conference call:

• Second-quarter revenue rose 22.7% to $336.3 million, reflecting the first full quarter of Breathe Right and LaCorium ownership; adjusted EPS increased about 6% to $1.13. Excluding acquisitions and foreign currency, revenue declined 1.6%, which management attributed partly to prior-quarter order timing.
• Clear Eyes production volatility prompted a cut to the full-year outlook. Prestige now expects fiscal 2027 revenue of $1.28 billion–$1.29 billion and adjusted EPS of $4.48–$4.55; it expects less than $20 million in Clear Eyes sales for the year and said supply recovery will take time.
• The company said its broader portfolio and recent acquisitions are performing well. First-half organic revenue grew about 1%, led by brands including Dramamine, TheraTears, Compound W, and Hydralyte; Breathe Right and LaCorium remain on track to contribute about $190 million in fiscal 2027 revenue.
• Prestige reported mid-teens e-commerce consumption growth and market-share gains for many leading brands, as shoppers seek value through online and mass-market channels. Management plans to use free cash flow to reduce debt, while forecasting at least $265 million in adjusted free cash flow for the year.

Prestige Consumer Healthcare Stock Down 2.9%

Shares of PBH stock traded down $1.29 on Friday, hitting $43.03. 1,127,190 shares of the stock were exchanged, compared to its average volume of 598,881. The company has a current ratio of 2.92, a quick ratio of 1.99 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $2.04 billion, a P/E ratio of 13.28, a price-to-earnings-growth ratio of 1.35 and a beta of 0.30. The business has a 50-day moving average of $48.17 and a 200 day moving average of $53.77. Prestige Consumer Healthcare has a fifty-two week low of $41.77 and a fifty-two week high of $71.07.

Analyst Ratings Changes

A number of brokerages have weighed in on PBH. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 22nd. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 29th. Finally, Canaccord Genuity Group dropped their price objective on shares of Prestige Consumer Healthcare from $72.00 to $70.00 and set a “buy” rating on the stock in a report on Friday. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $67.00.

Trending Headlines about Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Fiscal Q2 adjusted earnings were $1.13 per share, topping the $1.07 consensus, while revenue of $336.31 million exceeded estimates of about $329 million and rose 22.7% year over year. Prestige Consumer Healthcare fiscal 2027 second-quarter results
• Neutral Sentiment: Canaccord Genuity lowered its price target from $72 to $70 but maintained a Buy rating. The reduced target is a mild negative, though it still implies substantial upside from the cited share price. Canaccord Genuity Group stock recommendations
• Negative Sentiment: A recent report highlights PBH’s stock drop, but the provided article details do not specify what is driving the decline. The weakness despite an earnings and revenue beat may indicate investors are weighing concerns not explained in the available coverage. Prestige Consumer Healthcare stock dropped: what is driving attention now?

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.